Stanford researchers have developed a macrophage-targeted PEGylated liposome ("PEGosome") platform that selectively delivers polyethylene glycol (PEG) to inflammatory monocytes and macrophages driving neuroinflammation in diseases such as multiple sclerosis (MS), Alzheimer's d
Stanford researchers in Prof. Engleman and Reticker-Flynn's labs have created a novel cell therapy that targets the T-antigen, a prominent tumor-specific antigen, by leveraging the high avidity interactions between lectins and glycans.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.
Alloreaction-associated antigen (ARAg) is a novel member of the immunoglobulin superfamily. This invention's issued US patent claims composition of matter of ARAg polypeptides and nucleic acids encoding ARAg polypeptides.